Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Combined estrogen–androgen formulations
Estradiol benzoate/testosterone isobutyrate
Другие языки:

    Estradiol benzoate/testosterone isobutyrate

    Подписчиков: 0, рейтинг: 0
    Estradiol benzoate /
    testosterone isobutyrate
    Estradiol benzoate.svg
    Testosterone isobutyrate.svg
    Estradiol benzoate (top) and
    testosterone isobutyrate (bottom)
    Combination of
    Estradiol benzoate Estrogen
    Testosterone isobutyrate Androgen; Anabolic steroid
    Clinical data
    Trade names Femandren M, Folivirin
    Other names EB/TiB; EB/TiB
    Routes of
    administration    		 Intramuscular injection
    Identifiers
    CAS Number

    Estradiol benzoate/testosterone isobutyrate (EB/TiB), sold under the brand names Femandren M and Folivirin, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone isobutyrate (TiB), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. It is provided in the form of 1 mL ampoules containing 2.5 mg estradiol benzoate and 25 mg testosterone isobutyrate in a microcrystalline aqueous suspension and is administered by intramuscular injection once every 4 to 6 weeks. EB/TiB reportedly has a duration of about 14 to 21 days.

    The medication is available only in the Czech Republic and Slovakia. EB/TiB was originally developed and marketed by the Swiss pharmaceutical company Ciba and was introduced for medical use by 1953, following the development of testosterone isobutyrate in 1952. It was intermittently manufactured by Spofa and then Biotika and is now manufactured by BB Pharma.

    The effect of EB/TiB on gonadotropin levels in postmenopausal women have been studied.

    An oral tablet product with the same brand name of Femandren, containing ethinylestradiol and methyltestosterone, was marketed around the same time as Femandren M, and should not be confused with the injectable formulation.

    Androgen replacement therapy formulations and dosages used in women
    Route Medication Major brand names Form Dosage
    Oral Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg 1x/1–2 days
    Methyltestosterone Metandren, Estratest Tablet 0.5–10 mg/day
    Fluoxymesterone Halotestin Tablet 1–2.5 mg 1x/1–2 days
    Normethandronea Ginecoside Tablet 5 mg/day
    Tibolone Livial Tablet 1.25–2.5 mg/day
    Prasterone (DHEA)b – Tablet 10–100 mg/day
    Sublingual Methyltestosterone Metandren Tablet 0.25 mg/day
    Transdermal Testosterone Intrinsa Patch 150–300 μg/day
    AndroGel Gel, cream 1–10 mg/day
    Vaginal Prasterone (DHEA) Intrarosa Insert 6.5 mg/day
    Injection Testosterone propionatea Testoviron Oil solution 25 mg 1x/1–2 weeks
    Testosterone enanthate Delatestryl, Primodian Depot Oil solution 25–100 mg 1x/4–6 weeks
    Testosterone cypionate Depo-Testosterone, Depo-Testadiol Oil solution 25–100 mg 1x/4–6 weeks
    Testosterone isobutyratea Femandren M, Folivirin Aqueous suspension 25–50 mg 1x/4–6 weeks
    Mixed testosterone esters Climacterona Oil solution 150 mg 1x/4–8 weeks
    Omnadren, Sustanon Oil solution 50–100 mg 1x/4–6 weeks
    Nandrolone decanoate Deca-Durabolin Oil solution 25–50 mg 1x/6–12 weeks
    Prasterone enanthatea Gynodian Depot Oil solution 200 mg 1x/4–6 weeks
    Implant Testosterone Testopel Pellet 50–100 mg 1x/3–6 months
    Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

    See also



    Новое сообщение